Don’t Listen To Investment Gurus, Suggests Evidence.

Nowadays, it is common to invest in the stock market and related commodity markets. As such, the media is full of advertisements where so-called Gurus provide investment advice. Perhaps, the most common among these financial advice are “Stock Picks”, which is often mistakenly taken as a reputable source of information. For an average investor, who rely on expert advice, such stock picks are a potential goldmine because it seems that Gurus have done their homework. These financial guidance seems even more reliable when they are published in leading newspapers around the world. For instance, the leading Canadian newspaper, The Globe and Mail, provides stock picks. Similarly, CNBC is also famous for providing stock picks from Jim Cramer.

In a perfect world, advice from these experts should provide a viable investment strategy; however, a deeper look into the track record of these stock picks paints a grim picture. Not only some of the top investment Gurus do not have adequate investment profile to offer such advice, but their track record indicates failure. One of the well-known websites, which tracks investment advice of these Gurus, indicates that an investor can gain much better results without listening to the advice of the so-called Gurus in the media.

Therefore, investors should always look towards professional investment firms that are licensed to give such advice. For instance, Laidlaw & Company is a full-service investment banking and brokerage firm that offers personalized investment advice to high-profile investors. The 170 years of legacy enable professional investors to rely on the expertise of the firm. Under the guidance of Mathew Eitner, CEO, and James Ahren, Managing Partner, the company has over 150 highly-skilled employees who are licensed to deliver sound investment strategies. For more than a century, Laidlaw & Company remains a logical choice for professional investors.

 

Laidlaw & Company Showcases the Real Complexity of Medical Research

While medicine is only peripheral to my education, I’ve always found it to be a fascinating subject. The ways in which drug trials are conducted can be quite interesting. And of course there’s the simple issue of how people create something which will vastly improve the quality of life for people currently suffering from various ailments. That said, part of what makes it so interesting is the sheer complexity of medical research. But until recently I hadn’t considered that the funding for that research was probably just as complex.

They were involved in a legal dispute with Relmada Therapeutics. But even on the surface the case seemed very complex. With Laidlaw receiving a temporary restraining order and associated injunction due to concern that they might be spreading misleading information. What makes the case so interesting to me on a personal level is how the funding from Laidlaw ties into the medical advances of Relmada. I was quite aware that medical research was costly. But for some reason it just never occurred to me that the financing which went on for that research might be just as interesting a topic.

I decided to check out Laidlaw’s website to learn more about them. In turn, I actually learned more than I’d expected about two of the executives within the company. Matthew Eitner and James Ahern both had quite a bit of information about themselves on the site. And this really ended up being one of the deciding factors for me. I saw a lot of my own feelings about medicine reflected in their lists of charitable and business ventures. The work with Relmada was hardly a fluke.

Both men had apparently been working hard to ensure that companies could produce new medicines and provide the medical assistance that the world is so in need of. This makes me feel that the company is probably working under an honorable intent.